Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ARUK 2020 | Spectroscopic techniques for non-invasive diagnosis of Alzheimer’s disease

Mary Paraskevaidi • 27 Apr 2020
ARUK 2020
Alzheimer’s Disease Dementia

Mary Paraskevaidi, PhD, University of Central Lancashire, Lancashire, UK, and Imperial College London, London, UK, discusses the ability of blood-based spectroscopic technologies to differentiate normal controls from patients with Alzheimer’s disease according to their characteristic spectral information. This interview was recorded during an online conference call with The Video Journal of Dementia (VJDementia).

More from Mary Paraskevaidi

Benefits of early detection in Alzheimer's disease
4:00
Benefits of early detection in Alzheimer's disease
Mary Paraskevaidi • 27 Apr 2020
The role of blood spectroscopy in the Alzheimer's disease diagnostic process
2:00
The role of blood spectroscopy in the Alzheimer's disease diagnostic process
Mary Paraskevaidi • 27 Apr 2020
Alzheimer’s disease diagnosis: blood spectroscopy in the clinical setting
2:05
Alzheimer’s disease diagnosis: blood spectroscopy in the clinical setting
Mary Paraskevaidi • 27 Apr 2020
Alzheimer's disease outlook: sensitive diagnostic approaches & efficient treatments
1:45
Alzheimer's disease outlook: sensitive diagnostic approaches & efficient treatments
Mary Paraskevaidi • 27 Apr 2020

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
2:44
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
Jacqui Cannon • 5 Aug 2026
The Lewy Body Society's mission and impact
2:38
The Lewy Body Society's mission and impact
Jacqui Cannon • 5 Aug 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals